GT
CHRS icon

Glenmede Trust’s Coherus Oncology CHRS Stock Holding History

Glenmede Trust’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,559
Closed -$422K – 1300
2021
Q2 		$422K Buy
+30,559
New +$433K ﹤0.01% 928
2020
Q4 		– Sell
-928
Closed -$17K – 1401
2020
Q3 		$17K Buy
928
+345
+59% +$6.42K ﹤0.01% 1670
2020
Q2 		$10K Buy
583
+552
+1,781% +$9.34K ﹤0.01% 1853
2020
Q1 		$0 Hold
31
– – ﹤0.01% 3015
2019
Q4 		$0 Hold
31
– – ﹤0.01% 3024
2019
Q3 		$0 Hold
31
– – ﹤0.01% 3023
2019
Q2 		$0 Hold
31
– – ﹤0.01% 3078
2019
Q1 		$0 Hold
31
– – ﹤0.01% 3069
2018
Q4 		$0 Buy
+31
New +$359 ﹤0.01% 3024
2016
Q4 		– Sell
-31
Closed – – 2483
2016
Q3 		$0 Buy
+31
New +$846 ﹤0.01% 2587

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Glenmede Trust's CHRS Position: Q3 2021 in Review

Glenmede Trust sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 30,559 shares — an estimated $422K sold.

Glenmede Trust first reported a position in CHRS in Q3 2016 and held it in 10 quarters. The position peaked at $422K in Q2 2021. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

  • Glenmede Trust reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
  • Glenmede Trust sold 30,559 Coherus Oncology shares in Q3 2021, an estimated $422K.
  • Glenmede Trust first reported a position in Coherus Oncology in Q3 2016 and held it in 10 quarters.
  • Glenmede Trust's Coherus Oncology position peaked at $422K in Q2 2021.
  • 187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Glenmede Trust's 13F filing for Q3 2021, filed 15 Nov 2021.